125 related articles for article (PubMed ID: 37257316)
1. Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers.
El Kaoutari A; Fraunhoffer NA; Audebert S; Camoin L; Berthois Y; Gayet O; Roques J; Bigonnet M; Bongrain C; Ciccolini J; Iovanna JL; Dusetti NJ; Soubeyran P
EBioMedicine; 2023 Jun; 92():104634. PubMed ID: 37257316
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer.
Nicolle R; Blum Y; Duconseil P; Vanbrugghe C; Brandone N; Poizat F; Roques J; Bigonnet M; Gayet O; Rubis M; Elarouci N; Armenoult L; Ayadi M; de Reyniès A; Giovannini M; Grandval P; Garcia S; Canivet C; Cros J; Bournet B; Buscail L; ; Moutardier V; Gilabert M; Iovanna J; Dusetti N
EBioMedicine; 2020 Jul; 57():102858. PubMed ID: 32629389
[TBL] [Abstract][Full Text] [Related]
3. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis.
Mohamed Abd-El-Halim Y; El Kaoutari A; Silvy F; Rubis M; Bigonnet M; Roques J; Cros J; Nicolle R; Iovanna J; Dusetti N; Mas E
EBioMedicine; 2021 Sep; 71():103541. PubMed ID: 34425307
[TBL] [Abstract][Full Text] [Related]
4. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT
Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187
[TBL] [Abstract][Full Text] [Related]
5. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
6. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
7. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
[TBL] [Abstract][Full Text] [Related]
8. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
10. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
Han Y; Drobisch P; Krüger A; William D; Grützmann K; Böthig L; Polster H; Seifert L; Seifert AM; Distler M; Pecqueux M; Riediger C; Plodeck V; Nebelung H; Weber GF; Pilarsky C; Kahlert U; Hinz U; Roth S; Hackert T; Weitz J; Wong FC; Kahlert C
J Hematol Oncol; 2023 Feb; 16(1):7. PubMed ID: 36737824
[TBL] [Abstract][Full Text] [Related]
11. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.
Chang DZ; Ma Y; Ji B; Liu Y; Hwu P; Abbruzzese JL; Logsdon C; Wang H
J Hematol Oncol; 2012 Apr; 5():15. PubMed ID: 22475564
[TBL] [Abstract][Full Text] [Related]
12. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
Panzeri V; Manni I; Capone A; Naro C; Sacconi A; Di Agostino S; de Latouliere L; Montori A; Pilozzi E; Piaggio G; Capurso G; Sette C
Mol Oncol; 2021 Feb; 15(2):579-595. PubMed ID: 33159833
[TBL] [Abstract][Full Text] [Related]
13. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Liu Q; Cui M; Wang M; Hua S; Gao J; Liao Q
Front Immunol; 2021; 12():774435. PubMed ID: 35046938
[TBL] [Abstract][Full Text] [Related]
15. Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells.
Fraunhoffer NA; Moreno Vega AI; Abuelafia AM; Morvan M; Lebarbier E; Mary-Huard T; Zimmermann MT; Lomberk G; Urrutia R; Dusetti N; Blum Y; Nicolle R; Iovanna J
EBioMedicine; 2023 Jun; 92():104602. PubMed ID: 37148583
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
17. Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma.
Zhao Y; Altendorf-Hofmann A; Pozios I; Camaj P; Däberitz T; Wang X; Niess H; Seeliger H; Popp F; Betzler C; Settmacher U; Jauch KW; Bruns C; Knösel T
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1061-1068. PubMed ID: 28210844
[TBL] [Abstract][Full Text] [Related]
18. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Castillo J; Bernard V; San Lucas FA; Allenson K; Capello M; Kim DU; Gascoyne P; Mulu FC; Stephens BM; Huang J; Wang H; Momin AA; Jacamo RO; Katz M; Wolff R; Javle M; Varadhachary G; Wistuba II; Hanash S; Maitra A; Alvarez H
Ann Oncol; 2018 Jan; 29(1):223-229. PubMed ID: 29045505
[TBL] [Abstract][Full Text] [Related]
19. Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma.
Iuga C; Seicean A; Iancu C; Buiga R; Sappa PK; Völker U; Hammer E
Proteomics; 2014 Apr; 14(7-8):945-55. PubMed ID: 24459066
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
